Skip to main content

EGFR Gene Mutation clinical trials at UC Cancer

2 research studies open to eligible people

Showing trials for
  • 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma

    open to eligible people ages 18 years and up

    This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 18F-FDG PET imaging may help to detect changes in tumor glucose utilization, which may allow investigators to obtain an early read out on the impact of osimertinib on recurrent glioblastoma patients whose tumors have EGFR activation.

    at UCLA

  • Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

    open to eligible people ages 18 years and up

    This is a phase I/Ib, open-label, single-center, single-arm study of alisertib and osimertinib for patients with stage IV EGFR-mutated lung cancer, incorporating both a dose escalation and dose-expansion phase

    at UCSF

Last updated: